Prebreeding Immunization of Beef Cows

A number of infectious agents are potential threats to the fetus of a pregnant cow and may result in abortion. These agents include Leptospira sp., Campylobacter fetus and viruses such as infectious bovine rhinotracheitis (IBR) and bovine virus diarrhea (BVD). Maintenance in the cow of a high level of immunity to these agents during pregnancy can insure protection of the fetus. In particular, vaccines against BVD and IBR viruses can establish protective immunity throughout gestation. An appropriate vaccination regimen prior to breeding is required to establish this protective immunity. This can be achieved with a single dose of certain modified live virus vaccines, but those vaccines must be administered at least 30 days prior to breeding to avoid interference with conception. We have evaluated an oil-adjuvanted inactivated virus vaccine in cattle with differing immunological histories. Two doses of the vaccine administered 30 days apart to serologically negative animals induced appreciable levels of BVD and IBR anti-viral antibodies with persisting titers throughout gestation. In other experiments a single dose of the vaccine was administered to: (1) animals given two doses of the vaccine several months earlier, (2) animals previously vaccinated with other inactivated virus vaccines, or (3) animals previously vaccinated with modified live virus vaccine. The vaccine consistently induced marked anamnestic responses in these animals. Not only did mean titers rise, but a vast majority of individual animals responded. This contrasts with efforts to boost titers with modified live virus vaccines where the effect may be erratic among animals. The safety and efficacy of selected inactivated viral vaccines argues for their use in prebreeding immunization of beef cows.

Encore® Implant Use in Feedlot Steers

A feedlot demonstration utilizing Encore®, a new longterm implant product, was completed at the Allee Demonstration Farm at Newell, Iowa in 1999. Seventyone steers (697 lbs.) were allotted by weight and hide color and assigned to one of three treatments: 1) Encore® (43.9 mg estradiol = E) on day 0; 2) Encore® plus Component® TS (140 mg trenbolone acetate = ETS0) on day 0; or 3) Encore® on day 0 followed by Component® TS (ETS100) on day 100. Due to wide standard deviation in the weight of steers at the beginning of the demonstration, cattle were harvested in two groups. Approximately half of each treatment group was sorted by visual appraisal as to market readiness. Statistical interactions existed within treatment group between first and second harvest dates, therefore data were split and analyzed accordingly. In the first harvest group, ETS0 steers had higher marbling scores than ETS100 steers, and lower average daily gain than E steers and ETS100 steers. In the second harvest group, ETS0 steers had more fat at the 12th/13 rib than ETS100 steers, but did not differ from E steers. Marbling scores were also higher for ETS0 steers than either ETS100 or E steers in the second harvest group. Pooled data reveal that ETS0 steers had higher marbling scores than ETS100 steers and tended to have higher marbling scores than E steers. First harvest E and ETS100 steers had greater average daily gain than ETS0 steers. In the second harvest group, ETS0 steers had heavier final ending weights than E steers but did not differ from ETS100 steers. Final ending weights, rib eye area, fat thickness at the 12th/13th rib, KPH fat, and calculated yield grades did not differ among treatment groups in the pooled data.